Multiple Chinese Pharma Companies Receive Clinical Trial Approvals for Novel Therapies Targeting Advanced Solid Tumors

　　【Pharmaceutical Network Product InformationRecently, a piece of good news came from Wuhan Humanwell Innovative Drug Research and Development Center Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. Its independently researched and developed Class 1 new biological product for therapeutic use, HWS116 Injection, has been approved by the National Medical Products Administration to conduct clinical trials for advanced solid tumors. This news brings new hope for the development of drugs targeting advanced solid tumors.
 

Data show that HWS116 is a humanized monoclonal antibody targeting FGFR2b. It inhibits tumor growth by blocking fibroblast growth factor receptor-mediated signaling pathways and kills tumor cells through Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP). The overexpression of FGFR2b is closely related to highly invasive tumors such as gastric cancer, breast cancer, and intrahepatic cholangiocarcinoma. FGFR2b overexpression is found in approximately 30% of HER2-negative advanced gastric cancer patients. Developing therapies targeting FGFR2b can help achieve precise treatment for cancer patients with FGFR2b overexpression.
 

Advanced Solid Tumors Have Always Been a Challenge in the Medical Field
 

The clinical trial application for HY0001a for injection, developed by Sichuan Huiyu Pharmaceutical Co., Ltd. to treat advanced solid tumors, has been accepted, marking the official entry of this drug into the clinical trial phase. HY0001a for injection is a CDCP1 (CUB domain-containing protein 1) antibody-drug conjugate. Preclinical studies have shown that HY0001a exhibits excellent anti-tumor effects and good safety in various solid tumor models, demonstrating significant clinical development value.
 

Hansoh Pharma recently announced that HS-10529 tablets, a Class 1 new drug independently developed by the company, have received clinical trial approval from the National Medical Products Administration. The drug is being developed to treat advanced solid tumors with the KRAS G12D mutation. According to Hansoh Pharma's press release, this is a small molecule inhibitor targeting KRAS G12D with high selectivity. Preclinical efficacy studies have shown that HS-10529 exhibits promising preclinical efficacy, pharmacokinetic properties, and safety.
 

Recently, Fosun Henlius announced that the company's HLX43 for injection (an antibody-drug conjugate targeting PD-L1 and a novel DNA topoisomerase I inhibitor) ("HLX43") combined with Hansizhuang® (Serplulimab Injection) ("Hansizhuang®") for the treatment of patients with advanced/metastatic solid tumors has completed the first patient dosing in a phase 1b/2 clinical study within China (excluding Hong Kong, Macao, and Taiwan regions, hereinafter the same). This development provides a new direction for exploring combination therapy options for advanced solid tumors.
 

These pharmaceutical companies' active exploration and significant breakthroughs in the field of advanced solid tumor treatment have not only provided patients with more treatment options and survival hope but also demonstrated the continuous enhancement of China's pharmaceutical R&D capabilities. It is believed that, through the relentless efforts of numerous pharmaceutical companies, the medical challenge of advanced solid tumors will eventually be overcome, contributing to the health and well-being of patients worldwide.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.